AETHLON MEDICAL INC (AEMD) Dividend History

Company News

• Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

  Aethlon Medical's Hemopurifier device has demonstrated the ability to remove platelet-derived extracellular vesicles from plasma in a preclinical study. This data supports the ongoing oncology clinical trial in Australia and the potential use of the Hemopurifier in various disease indications.

  Benzinga
• Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

  Aethlon Medical published preclinical data on its Hemopurifier device, which demonstrated the removal of extracellular vesicles and microRNAs from renal perfusates. The data suggests the Hemopurifier has potential applications in organ transplantation beyond its existing focus on oncology and infectious diseases.

  Benzinga
• Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

  Aethlon Medical, a medical therapeutic company, will present at the Emerging Growth Conference on February 19, 2025. The presentation will be an opportunity for investors to interact with the company's CEO in real-time.

  Benzinga
• Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

  Aethlon Medical, a medical therapeutic company, announced that it will release its fiscal third quarter financial results and host a conference call on February 12, 2025. The company's Hemopurifier device is designed to combat cancer and life-threatening viral infections.

  Benzinga
• Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

  Aethlon Medical announced the treatment of the first patient in its Australian clinical trial of the Hemopurifier, a device designed to remove tumor-derived extracellular vesicles and enhance the effectiveness of anti-PD-1 cancer therapies.

  Benzinga